CVRx, Inc.
NASDAQ•CVRX
CEO: Mr. Kevin Hykes
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2021-06-30
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Contact Information
Market Cap
$207.07M
P/E (TTM)
-3.9
25.9
Dividend Yield
--
52W High
$13.34
52W Low
$4.30
52W Range
Rank61Top 91.5%
2.0
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Financial Dashboard
Q4 2025 Data
Revenue
$16.02M+0.00%
4-Quarter Trend
EPS
-$0.46+0.00%
4-Quarter Trend
FCF
-$9.83M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Growth 10% Revenue reached $56.7M USD, growing 10% over prior year; U.S. sales up 10% to $51.9M USD.
Gross Margin Improvement Gross profit increased 13% to $48.3M USD; Gross margin improved to 85% from 84% due to efficiency.
Operating Loss Narrowed Operating loss narrowed 14% to $51.3M USD; Net loss decreased 11% to $53.3M USD for 2025.
Sales Territory Expansion U.S. implanting centers grew to 252 from 223; U.S. sales territories expanded to 53 from 48.
Risk Factors
Sustained Operating Losses History of significant net losses ($53.3M USD in 2025) expected to continue, impacting capital raising ability.
Single Product Dependency Highly dependent on Barostim sales; failure to increase U.S. market acceptance materially affects liquidity and results.
Limited Sales Experience Limited commercial sales experience; inability to retain or grow sales capabilities prevents sustained increasing product revenue.
Supply Chain Vulnerability Reliance on limited third-party suppliers for critical components creates vulnerability to shortages and performance degradation.
Outlook
Expanded Clinical Trial Initiated BENEFIT-HF trial in Jan 2026 to evaluate expanded population; success could raise U.S. market to $30.5B.
Future Financing Secured Borrowed $10.0M in Jan 2026; maintains ATM capacity up to $50.0M for future commercialization investments.
R&D Focus Areas Near-term R&D focuses on technological advancement; long-term goal is expanding indications to hypertension and arrhythmias.
Sales Force Growth Plan Plan to expand U.S. direct sales force and increase payer awareness to drive future revenue growth.
Peer Comparison
Revenue (TTM)
$2.76B
$348.67M
$270.28M
Gross Margin (Latest Quarter)
93.9%
91.3%
87.3%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| VMD | $379.32M | 24.9 | 10.9% | 7.4% |
| CERS | $345.91M | -22.0 | -26.4% | 43.7% |
| FHTX | $291.15M | -4.2 | 88.3% | 20.8% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
9.1%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:Apr 29, 2026
EPS:-$0.52
|Revenue:$14.06M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data